IRCT20190324043105N2已完成2 期
Treatment effect of Rituximab in myasthenia gravis patients resistant to the standard treatment
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 75 years（—）
- 性别
- All
入选标准
- •The patient has myasthenia gravis disease (positive AB test for AChR and MUSK *, evidence of myasthenia gravis disease in RNS test, positive Edrophonium test in the patient, and Chest MDCT for thymus involvement). * in Double Seronegative patients, both of these antibodies are negative; Therefore, the other 3 criteria used for diagnosis.
- •In the patients positive for Anti AchR or negative for both antibodies, these characteristics must present: resistance to corticosteroid therapy or is contraindication; resistance to azathioprine treatment or its side effects occur which necessitate the discontinuation of the drug.
- •In the patients positive for Anti MUSK, resistance to corticosteroid therapy or is contraindication, must occur.
- •The patient doesn't have Eaton Lambert syndrome.
- •The patient doesn't administrate unconventional medications (herbal, acupuncture, and etc.).
- •Desire of the patient to participate in this study and Signing Written Informed Consent.
排除标准
- 未提供
研究者
相似试验
尚未招募
不适用
Rituximab for intractable myasthenia gravismyasthenia gravisJPRN-UMIN000016564Tokushima University Hospital1
已完成
1 期
A Pilot Trial of Rituxan in Refractory Myasthenia GravisRefractory Myasthenia GravisNCT00619671University of Vermont10
已完成
不适用
Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical studyMuSK antibody-positive myasthenia gravisJPRN-UMIN000012089Department of Neurology University of Tokyo, Graduate School of Medicine5
已完成
2 期
BeatMG: Phase II Trial of Rituximab In Myasthenia GravisMyasthenia GravisNCT02110706Yale University52
招募中
不适用
Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIGMyasthenia gravisJPRN-UMIN000015019Kansai medical university20